Krähn G, Kaskel P, Sander S, Waizenhöfer P J, Wortmann S, Leiter U, Peter R U
Department of Dermatology, University of Ulm, 89070 Ulm/Donau, Germany.
Anticancer Res. 2001 Mar-Apr;21(2B):1311-6.
Lactate-dehydroxynase (LDH) has been described as a leading blood parameter in patients with melanoma metastases. However, recent data indicates that levels of S100 as well as melanoma inhibiting activity (MIA) in peripheral blood, correlate with melanoma progression. The aim of this study was to evaluate tumor markers S100, MIA, LDH and albumin in peripheral blood of 373 melanoma patients. 284 patients presented with in-situ or UICC stage I/II, and 89 with stage III/IV (54 tumor-free, 29 with newly occurred metastases). For newly occurred metastases, sensitivity was highest for S100 in peripheral blood (0.86), followed by MIA (0.80), LDH (0.48), and albumin (0.15). Specificity for albumin (0.99) and LDH (0.98) was higher than for S100 (0.91) and MIA (0.62). This data indicate that S100 in peripheral blood as compared to MIA, LDH and albumin appears to be the most appropriate tumor marker for newly occurred melanoma metastases.
乳酸脱氢酶（LDH）被认为是黑色素瘤转移患者的一项主要血液指标。然而，最近的数据表明，外周血中S100水平以及黑色素瘤抑制活性（MIA）与黑色素瘤进展相关。本研究的目的是评估373例黑色素瘤患者外周血中的肿瘤标志物S100、MIA、LDH和白蛋白。284例患者为原位癌或国际抗癌联盟（UICC）I/II期，89例为III/IV期（54例无肿瘤，29例有新发生的转移灶）。对于新发生的转移灶，外周血中S100的敏感性最高（0.86），其次是MIA（0.80）、LDH（0.48）和白蛋白（0.15）。白蛋白（0.99）和LDH（0.98）的特异性高于S100（0.91）和MIA（0.62）。这些数据表明，与MIA、LDH和白蛋白相比，外周血中的S100似乎是新发生黑色素瘤转移灶最合适的肿瘤标志物。
